The affect of method of preparation, granulating fluid, binder, concentration of binder and the composition of matrix on in vitro release of Alfuzosin was studied with a view to develop extended release formulations for Alfuzosin Hcl. Alfuzosin is a uroselective alpha -1 adrenergic antagonist indicated for the management of moderate to severe benign prostatic hyperplasia. The drug is freely soluble in water, has low dose and short biological half life, hence it is suitable for oral extended release formulations. Extended release formulations for Alfuzosin are necessary to maintain uniform plasma concentrations of Alfuzosin, to reduce frequency of administration and to eliminate cardiovascular adverse effects attributed by Alfuzosin. The drug-excipient compatibility studies were carried out with IR spectral studies. The selected excipients were found to be compatible with the drug. Alfuzosin tablets were prepared by wet granulation method. The prepared granules of Alfuzosin were evaluated for bulk density, tapped density, % compressibility index and hausner’s ratio. Formulated tablets were evaluated for uniformity of weight, assay and in-vitro drug release studies. The in vitro release rate of drug is dependent upon different formulation variables. The release rate of drug from the extended release tablets can be governed by the type of the Polymer and the molecular weight of the polymer employed in the preparation of the tablets. The tablets containing 65.42%w/w lactose, 30%w/w HPMC K 100 M yielded the drug release up to 24 hrs and hence this formulation was selected for the extended release of Alfuzosin.
Loading....